QLT PhotoTherapeutics Inc. regulatory update

The FDA approved QLTIF's light activated drug, Photofrin (porfimer sodium), to treat advanced esophageal cancer. The product is approved for palliative treatment of patients with totally obstructing tumors and partially obstructing esophageal cancers that are unsuitable for treatment with thermal laser therapy.

The approval includes marketing clearance for laser systems and a fiber optic used to activate Photofrin. ...